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BACKGROUND: Myocardial fibrosis is a hallmark of cardiac remodeling 
and functionally involved in heart failure development, a leading cause 
of deaths worldwide. Clinically, no therapeutic strategy is available that 
specifically attenuates maladaptive responses of cardiac fibroblasts, the 
effector cells of fibrosis in the heart. Therefore, our aim was to develop 
novel antifibrotic therapeutics based on naturally derived substance library 
screens for the treatment of cardiac fibrosis.
METHODS: Antifibrotic drug candidates were identified by functional 
screening of 480 chemically diverse natural compounds in primary human 
cardiac fibroblasts, subsequent validation, and mechanistic in vitro and 
in vivo studies. Hits were analyzed for dose-dependent inhibition of 
proliferation of human cardiac fibroblasts, modulation of apoptosis, and 
extracellular matrix expression. In vitro findings were confirmed in vivo 
with an angiotensin II–mediated murine model of cardiac fibrosis in both 
preventive and therapeutic settings, as well as in the Dahl salt-sensitive rat 
model. To investigate the mechanism underlying the antifibrotic potential 
of the lead compounds, treatment-dependent changes in the noncoding 
RNAome in primary human cardiac fibroblasts were analyzed by RNA 
deep sequencing.
RESULTS: High-throughput natural compound library screening 
identified 15 substances with antiproliferative effects in human cardiac 
fibroblasts. Using multiple in vitro fibrosis assays and stringent selection 
algorithms, we identified the steroid bufalin (from Chinese toad venom) 
and the alkaloid lycorine (from Amaryllidaceae species) to be effective 
antifibrotic molecules both in vitro and in vivo, leading to improvement 
in diastolic function in 2 hypertension-dependent rodent models of 
cardiac fibrosis. Administration at effective doses did not change plasma 
damage markers or the morphology of kidney and liver, providing the first 
toxicological safety data. Using next-generation sequencing, we identified 
the conserved microRNA 671-5p and downstream the antifibrotic 
selenoprotein P1 as common effectors of the antifibrotic compounds.
CONCLUSIONS: We identified the molecules bufalin and lycorine as drug 
candidates for therapeutic applications in cardiac fibrosis and diastolic 
dysfunction.
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In the healthy heart, extracellular matrix is essential to maintain both structure and integrity of the or-gan. In contrast, cardiac stress results in excessive 
production of extracellular matrix, leading to cardiac 
fibrosis.1,2 Fibrosis subsequently triggers myocardial 
stiffness, ultimately impairing left ventricular (LV) dia-
stolic and later systolic function.3 Myocardial fibrosis 
favors progression to end-stage heart failure (HF), ar-
rhythmias, and ischemia and therefore correlates with 
an increased mortality in patients, even under state-
of-the-art treatment.4 Thus, cardiac fibrosis constitutes 
not only a major determinant for the clinical outcome 
of patients with HF but also a therapeutic target of 
utmost interest and importance.
Thus, we applied a naturally derived substance library 
screen to search for novel antifibrotic, cardioprotective 
lead compounds for further development into new an-
tifibrotic therapeutics. Subsequent refining strategies 
of functional in vitro and in vivo studies uncovered the 
cardiac glycoside bufalin and the alkaloid lycorine. Both 
molecules potently repressed the fibrotic response in 
human cardiac fibroblasts (HCFs), and both prevented 
and reversed fibrosis in cardiac fibrosis mouse models 
(implanted osmotic minipumps for systemic angioten-
sin II [Ang II] infusion). In addition, inhibition of cardiac 
fibrosis, along with improvement in diastolic perfor-
mance, could be confirmed in the Dahl salt-sensitive rat 
model of HF with diastolic dysfunction. Previously, these 
2 identified drug candidates were discovered to exhibit 
antitumor activities in preclinical studies.5–16 Moreover, 
neuroprotective, anti-inflammatory, antiosteoporotic, 
and antimicrobial effects of the compounds have been 
described.7,12,17–20 However, the application of bufalin or 
lycorine in the prevention or treatment of cardiac fibro-
sis and diastolic dysfunction has never been explored. In 
addition, their mode of action or influence on noncod-
ing RNAs involved in cardiac fibrosis is unknown.
METHODS
Animal Experiments
All animal studies involving mice were performed in accor-
dance with the relevant guidelines and regulations and 
with the approval of the Niedersächsisches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit (Germany), the 
Brigham and Women’s Hospital, and the Ethical Committee for 
Animal Experimentation of the University of Navarra (Spain).
Statistical Analysis
All in vitro experiments were performed ≥3 independent 
times, as indicated in the figure captions, in duplicate, tripli-
cate, or quadruplicate wells. The independent number of ani-
mals in each group is indicated in the figure legends. Data are 
displayed as mean of independent experiments/independent 
animal samples±SEM if not otherwise specified in the figure 
legend. Statistical analysis was carried out with the GraphPad 
Prism 6 software (GraphPad Prism Software Inc, San Diego, 
CA). For comparison of 2 groups, unpaired 2-tailed Student t 
test was applied, and for analysis of ≥3 groups, 1-way ANOVA 
with Turkey and 2-way ANOVA with Tukey multiple-compar-
isons test were performed if not otherwise specified in the 
figure legend. In all cases, a value of P≤0.05 was considered 
statistically significant.
A detailed Methods section is available in the online-only 
Data Supplement.
The data and analytical methods will be made available 
to other researchers for purposes of reproducing the results 
or replicating the procedure. Study materials can be pro-
vided only when a material transfer agreement is signed and 
if still available.
RESULTS
Natural Compound Screening Identifies 
Bufalin and Lycorine as Specific 
Antifibrotic Molecules in HCFs
Excessive accumulation of extracellular matrix in the 
diseased heart is caused by an increase in both pro-
liferation rates and collagen production of cardiac fi-
broblasts. To uncover natural compounds suppressing 
Clinical Perspective
What Is New?
• Natural compound library screening in human car-
diac fibroblasts identified novel compounds with 
antifibrotic properties.
• The compounds bufalin and lycorine show highly 
potent antifibrotic effects in vitro and in vivo and 
improve diastolic function in relevant models of 
heart failure.
• We provide evidence for cardioprotective, antifi-
brotic effects of the natural compounds bufalin and 
lycorine with a promising safety-tolerability profile, 
laying the groundwork for prospective preclini-
cal and clinical studies with the aim of specifically 
treating cardiac fibrosis and diastolic dysfunction.
What Are the Clinical Implications?
• Although some state-of-the-art medications may 
improve fibrosis and diastolic dysfunction, no ther-
apeutic strategy currently is available that is spe-
cifically designed to target fibroblasts, the effector 
cells of fibrosis in the heart.
• We provide strong evidence of natural compound–
based preventive and therapeutic strategies against 
the development of cardiac fibrosis and diastolic dys-
function in clinically relevant models of heart failure.
• Preclinical and clinical development of specific car-
diac antifibrotic molecules as presented here could 
lead to transformational changes in the treat-
ment of patients with cardiac fibrosis and diastolic 
dysfunction.
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Figure 1. Bufalin and lycorine potently and specifically repress fibrotic responses in human cardiac fibroblasts (HCFs).
A, Filtering strategy, followed by in vitro and in vivo pipeline of analysis, uncovers antifibrotic lead compounds bufalin and lycorine. B, Functional screen of 480 
naturally derived substances in vitro yielding natural compounds inhibiting the proliferation of HCFs. The cells were incubated for 24 hours as indicated, and prolif-
eration of HCFs was measured by BrdU-ELISA. Fifteen candidates inhibiting the fibroblast proliferation fold change (FC) ≥75% are highlighted by the red rectangle. 
C, Dose-dependent inhibitory effects of bufalin, gitoxigenin, lycorine, anisomycin, and geldanamycin on proliferation of HCFs. The cells were incubated for 24 
hours as indicated, and the proliferation of HCFs was measured by BrdU-ELISA (1-way ANOVA, Dunnett multiple-comparisons test, n=4-6). D, Positively validated 
hits do not induce cell death in HCFs. Cells were treated with respective compounds for 24 hours as indicated and (Continued )
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fibrotic responses in cardiac fibroblasts, proliferation of 
HCFs was studied after incubation with 480 individu-
al compounds, selected from a database comprising 
150 000 natural products for a maximum of chemical 
diversity with the OptiSim algorithm (Figure  1A and 
1B). Applying a selection threshold of fibroblast prolif-
eration inhibition fold change ≥75%, we identified 15 
candidates, of which 5 inhibited proliferation rates in 
a dose-dependent manner (Figure  1B and 1C). Next, 
we excluded cell death to be involved in the observed 
decrease in proliferation triggered by these compounds 
(bufalin, gitoxigenin, lycorine, anisomycin, and geldan-
amycin). Therefore, HCFs were treated with respective 
compounds using the effective doses and subjected to 
fluorescence-activated cell sorter analysis after annexin-
7AAD staining (Figure 1D). To confirm fibroblast speci-
ficity of the remaining candidates, potential effects on 
proliferation rates of the cardiomyocyte cell line HL-1 
were studied. As depicted in Figure 1A, except for an-
isomycine, all tested substances acted specifically on 
cardiac fibroblasts only, as evidenced by no impact on 
the proliferation of HL-1 cells (Figure 1E). On the basis 
of these selection criteria, the cardiac glycoside bufa-
lin and the alkaloid lycorine were further assayed for 
suppression of collagen type I, α1 expression, the rigid 
and highly cross-linked extracellular matrix component 
produced in excess by activated fibroblasts. Treatment 
of HCFs with the 2 lead compounds, and in particular 
with bufalin, effectively decreased fibroblast collagen 
type I, α1 protein levels (Figure 1F). Likewise, collagen 
amounts secreted into the supernatant of HCFs were 
reduced by bufalin (Figure IA in the online-only Data 
Supplement).
To further elaborate on fibroblast-specific actions 
of bufalin and lycorine, we determined the cell size of 
neonatal rat cardiomyocytes stimulated with Ang II on 
treatment with the 2 lead drug candidates. Neither bu-
falin nor lycorine counteracted the hypertrophic growth 
of cardiomyocytes in vitro stimulated by Ang II (Figure 
IB and IC in the online-only Data Supplement). Of note, 
lycorine but not bufalin exerted slight inhibitory ef-
fects on proliferation of the rat renal fibroblast cell line 
NRK49F (Figure ID in the online-only Data Supplement). 
In contrast, bufalin in particular inhibited proliferation 
of primary human pulmonary fibroblasts (Figure IE in 
the online-only Data Supplement). These results might 
suggest a potential therapeutic implication of the sub-
stances not only in cardiac but also in renal or pulmo-
nary fibrotic diseases, respectively.
Bufalin and Lycorine Prevent Fibrosis 
and Preserve Cardiac Function in Ang 
II–Induced Cardiac Remodeling
To verify whether the identified antifibrotic substanc-
es prevent fibrosis development at early stages also in 
vivo, C57BL/6N mice were infused with Ang II by subcu-
taneously implanted minipumps for 2 weeks. The natu-
ral substances (dissolved in dimethyl sulfoxide) or the 
solvent alone (as control) was injected intraperitoneally 
every other day until the end point, beginning 1 day 
after the start of Ang II infusion. Histological sections 
of the heart were studied for fibrosis development, and 
cardiac function was assessed both echocardiographi-
cally and hemodynamically. A schematic representation 
of the preventive in vivo study is depicted in Figure 2A. 
Ang II infusion led to a significant decrease in body 
weight (Figure IF in the online-only Data Supplement) 
which linked with increased ratios of heart to body 
weight in animals infused with the solvent only (con-
trols); however, bufalin or lycorine did not significantly 
prevent this effect (Figure 2B). Treatment with bufalin 
significantly prevented cardiac fibrosis, as shown by a 
reduction of collagen deposition in histological sections 
of the hearts (Figure 2C). Lycorine showed also global 
antifibrotic effects, although this was of borderline sig-
nificance (Figure 2C). However, further assessment of 
regional fibrosis measurements showed significant re-
ductions in interstitial fibrosis and in perivascular fibrosis 
by treatment with bufalin. Treatment with lycorine also 
prominently decreased interstitial fibrosis; however, the 
significance of this effect was borderline (Figure IIA–IIC 
in the online-only Data Supplement).
Fibrosis development is associated with diastolic and 
eventually progression to systolic dysfunction in hyper-
tensive mice, hereby closely recapitulating pathologi-
cal remodeling common in fibrotic cardiac disease in 
humans. Thus, we evaluated mitral inflow and tissue 
Doppler signals to assess the effect of the compounds 
on diastolic function (Figure  2D). Echocardiographic 
evaluation of diastolic function revealed early signs 
of diastolic dysfunction with impaired relaxation after 
2 weeks of Ang II treatment (Figure  2D through 2H) 
with decreased E/A ratio and increased deceleration 
time accompanied by slower peak mitral annular ve-
locity, E’. Both compounds conferred improvements of 
relaxation, as evidenced by a decrease of the myocar-
dial performance index (MPI) and the deceleration time, 
as well as rescued E/A ratios and E’. The increase of E’ 
Figure 1 Continued. subjected to fluorescence-activated cell sorter analysis after annexin-7AAD staining (unpaired t test, n=3). E, Dose-dependent inhibitory ef-
fects of bufalin and lycorine on proliferation of HCFs are fibroblast specific, as evidenced by no impact of the same concentrations of respective substances on the 
proliferation of the cardiomyocyte cell line HL-1. Cells were treated with the compounds for 24 hours as indicated, and proliferation of HL-1 cells was measured 
by BrdU-ELISA (1-way ANOVA, Dunnett multiple-comparisons test, n=3). F, Bufalin and, to a lesser extent, lycorine decrease expression levels of collagen type I, 
α1 (COL1A1) in HCFs shown in a representative Western blot. Cells were treated with respective substances for 24 hours as indicated, lysed, and analyzed for 
COL1A1 protein levels (normalized to GAPDH; unpaired t test). All values from C through F are presented as mean±SEM. DMSO indicates dimethyl sulfoxide; and 
ns, not significant. *P<0.05, **P<0.01, ***P<0.001, #P=0.265. 
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Figure 2. Bufalin and lycorine protect from angiotensin II (Ang II)–induced fibrotic cardiac disease in mice.
A, Schematic representation of the preventive in vivo study using a murine model of hypertensive heart disease. Diastolic dysfunction was induced in C57BL/6 
mice via implantation of Ang II–filled minipumps, and bufalin or lycorine was injected intraperitoneally every other day during 2 consecutive weeks starting 1 
day after the operation. Fourteen days after the operation, hearts were explanted for biochemical and histological analysis. B, Reduced heart-to-body weight 
ratios (HW/BW) on treatment as indicated compared with control animals (1-way ANOVA, Tukey multiple-comparisons test, n=14/17/17/14). C, Prevention of 
collagen deposition shown in representative images of cardiac histological sections of the whole heart and quantification of Picrosirius red–stained areas on 
administration of bufalin and lycorine (1-way ANOVA, Tukey multiple-comparisons test, n=10/11/10/11), scale bar=1 mm. (Continued )
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indicates true improvement of tissue function, making 
pseudonormalization unlikely (Figure 2H). The preven-
tive effect of lycorine on MPI and of bufalin on E/A ratio 
was of borderline significance (Figure 2D through 2G). 
Hemodynamic pressure-volume measurements were 
performed to assess LV compliance. Treatment with bu-
falin or lycorine completely counteracted the develop-
ment of passive stiffness of the LV caused by the Ang 
II infusion, as evidenced by a reduction of the end-di-
astolic pressure-volume relationship (Figure 2I). In line 
with the heart weight data (Figure  2B), cardiac mass 
measured by echocardiography was slightly increased 
but unaffected by bufalin or lycorine in the Ang II–treat-
ed groups (Figure 2J).
Bufalin and lycorine were detectable in cardiac tis-
sue (and plasma) of mice, confirming their uptake into 
the heart on systemic delivery (Figure IID and IIE in the 
online-only Data Supplement). Moreover, continuous 
monitoring of systolic and diastolic blood pressures in 
mice via telemetry showed that neither bufalin nor ly-
corine had any regulative impact on hypertension in-
duced by Ang II, excluding the possibility that bufalin or 
lycorine confers cardioprotection by reducing elevated 
blood pressure (Figure IIF and IIG in the online-only Data 
Supplement). Of note, Ang II infusion for 8 weeks did 
not increase the number of terminal desoxynucleotidyl 
transferase–mediated dUTP-biotin nick-end labeling–
stained cells in the myocardium, ruling out the possibili-
ty that bufalin or lycorine exerts cardioprotective effects 
by diminishing cardiomyocyte death (Figure IIH in the 
online-only Data Supplement). In line with this, the bcl-
2–associated X protein/b-cell lymphoma 2 (BAX/BCL2) 
ratio based on mRNA levels in the same cardiac tissues 
remained comparable within all groups tested (Figure III 
in the online-only Data Supplement).
The anti-inflammatory effects of bufalin and lycorine 
have previously been described. In particular, attenua-
tion of proinflammatory mediators such as tumor ne-
crosis factor-α and interleukin (IL)-1β could be demon-
strated.19,21 Inflammation commonly precedes fibrosis 
development in cardiac diseases. We therefore mea-
sured mRNA levels of tumor necrosis factor-α and IL-1β 
in whole-heart tissues. Although trends toward lower 
transcriptional activities of tumor necrosis factor-α and 
IL-1β occurred on bufalin treatment, Ang II infusion did 
not lead to any significant activation of tumor necro-
sis factor-α or IL-1β expression (Figure IIJ and IIK in the 
online-only Data Supplement).
In terms of the safety and tolerability of the com-
pounds, no signs of kidney and liver damage by plas-
ma markers were found (Figure IIIA in the online-only 
Data Supplement). This provides the first promising 
data for further development of the 2 substances, bu-
falin and lycorine.
Bufalin and Lycorine Reverse Fibrosis 
and Recover Cardiac Function in Ang 
II–Induced Cardiac Remodeling
Our next aim was to test the beneficial effects of the 
identified antifibrotic compounds on cardiac fibrosis 
and function in a therapeutic setting, that is, when car-
diac fibrosis was already established. Therefore, treat-
ment of Ang II–infused mice with bufalin or lycorine 
was started at a time point when cardiac fibrosis and 
diastolic dysfunction were already evident. Bufalin, ly-
corine, or the solvent was injected intraperitoneally ev-
ery other day for 6 consecutive weeks starting 2 weeks 
after start of the Ang II treatment (Figure  3A). Treat-
ment with both compounds significantly reduced over-
all fibrosis in the myocardium (Figure 3B and Figure IIIB 
in the online-only Data Supplement) without affecting 
cardiomyocyte size (Figure IIIC and IIID in the online-
only Data Supplement). The strong antifibrotic effect 
of both compounds is evidenced by detailed analysis 
of the perivascular and interstitial regions (Figure IVA 
through IVC in the online-only Data Supplement).
Hemodynamic and echocardiography assessment 
revealed the progression of diastolic dysfunction to a 
more severe stage, evidenced by enlarged left atria, 
reduced dP/dtmin, statistically significant increase of 
tau and end-diastolic pressure-volume relationship, in-
creased E/A ratio, highly increased MPI and peak E/E’, 
and decreased deceleration time (Figure 3D through 
3H, Figure IVD and IVE in the online-only Data Supple-
ment, and Table  1). Both compounds were able to 
partly reverse diastolic dysfunction; bufalin recovered 
hemodynamic parameters (dP/dtmin, tau, and end-
diastolic pressure-volume relationship) and both MPI 
and deceleration time (Figure 3C through 3E and Figure 
IVE in the online-only Data Supplement); and lycorine 
showed protective effects on diastolic dysfunction to 
a lesser degree with borderline significance (Figure 3D 
and 3E). Both compounds reduced the elevated E/A ra-
tio and the left atrial area (Figure 3F and Table 1), and 
tissue Doppler imaging confirmed faster tissue motion 
Figure 2 Continued. D, Isovolumic contraction time, isovolumic relaxation time, aortic ejection time, and E and A waves are measured by pulsed-wave (PW) 
Doppler from the apical 4-chamber view from the lateral mitral valve (top). Early (E’) and atrial (A’) peak velocities are measured from tissue Doppler signal at the 
mitral annulus (bottom). Preservation of myocardial performance index (MPI; E; 1-way ANOVA, Tukey multiple-comparisons test, n=11/21/16/12), deceleration 
time (F; 1-way ANOVA, Tukey multiple-comparisons test, n=11/21/16/12), improvement of peak E/A ratio (G; 1-way ANOVA, Tukey multiple-comparisons test, 
n=8/16/11/7), and improved E’ peak value (H; 1-way ANOVA, Tukey multiple-comparisons test, n=8/16/11/7) after treatment with compounds as indicated. I, 
Preservation of left ventricular (LV) compliance by bufalin or lycorine, assessed by end-diastolic pressure-volume relationship (EDPVR) obtained by linear fits of the 
EDPVR slope, resulting from the shift of pressure-volume loops after transient vena cava occlusions (1-way ANOVA, Tukey multiple-comparisons test, n=8/9/6/8). J, 
Significant increase in LV mass by Ang II infusion in animals treated with the solvent only (controls) but not in mice treated with bufalin or lycorine (1-way ANOVA, 
Tukey multiple-comparisons test, n=8/11/9/9). All values from B through J are presented as mean±SEM. DMSO indicates dimethyl sulfoxide. *P<0.05. **P<0.01. 
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Figure 3. Bufalin and lycorine reverse established fibrosis and improve heart function in hypertensive mice.
A, Therapeutic in vivo study using a murine model of systemic hypertension. Bufalin, lycorine, or dimethyl sulfoxide (DMSO) was injected intraperitoneally every 
other day for 6 consecutive weeks starting 2 weeks after the implantation of minipumps filled with angiotensin II (Ang II). B, Significant amelioration of cardiac 
fibrosis in established diastolic heart failure on treatment with bufalin and lycorine by 50% (2-way ANOVA, Tukey multiple-comparisons test, n=19/8/7/17/18/16). 
C, Representative images of hemodynamic pressure-volume loops. Both compounds were able to partly reverse diastolic dysfunction; bufalin recovered hemo-
dynamic parameters (dP/dtmin, tau, and end-diastolic pressure-volume relationship [EDPVR]) compared with the Ang II group. D through F, Strong trend of 
reduction of myocardial performance index (MPI; 1-way ANOVA, n=19/8/7/17/18/16) and prolongation of deceleration time (2-way ANOVA, Tukey multiple-com-
parisons test, n=19/8/7/17/18/16) by the lead compounds and decreased peak E/A (2-way ANOVA, Tukey multiple-comparisons test, n=18/8/7/14/15/15) on 
treatment with compounds. G, Strong trend in reduction of peak E/E’ on treatment with both bufalin and lycorine (2-way ANOVA, Tukey multiple-comparisons 
test, n=14/8/7/14/14/15). H, Significant improvement of load-independent EDPVR by bufalin and lycorine on systemic hypertension (2-way ANOVA, Tukey 
multiple-comparisons test, n=14/8/7/14/14/15). I, Significant increase in left ventricular (LV) mass by Ang II infusion in animals treated (Continued ) 
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during diastole on treatment with bufalin as represent-
ed by recovery of E/E’ ratios in Ang II–treated mice (Fig-
ure 3G, Figure IVE in the online-only Data Supplement, 
and Table  1). Moreover, 2D speckle-tracking strain 
echocardiography uncovered a significant reversal of 
the downshift of both radial and longitudinal strains 
(percent) in the base, middle, and apical regions of the 
heart triggered by Ang II infusion on treatment with 
bufalin and lycorine (Table 2 and Figure IVF through IVH 
in the online-only Data Supplement). Pressure-volume 
analysis revealed that bufalin and lycorine improved LV 
compliance, as evidenced by a significant reduction of 
end-diastolic pressure-volume relationship, a load-in-
dependent parameter of LV stiffness (Figure 3H), with-
out affecting end-systolic pressure-volume relationship 
(Figure IVD in the online-only Data Supplement). Thus, 
systematic assessment of cardiac function unveiled a 
prominent reduction of passive stiffness of the LV on 
systemic hypertension by the antifibrotic activity of the 
lead compounds (especially in the therapeutic setup, 
eg, a situation in which treatment started only after 
fibrosis and diastolic dysfunction were already estab-
lished). Ang II infusion significantly increased LV mass in 
animals infused with the solvent only (controls), which 
remained unchanged in mice treated with bufalin or 
lycorine (Figure 3I). There was no difference between 
treatments within the control groups (bufalin or lyco-
rine only versus vehicle only groups), indicating that 
the compounds are without cardiac effects under basal 
conditions (Figure 3B through 3I).
To provide first insight into safety and tolerability also 
after the prolonged administration of the substances (6 
weeks), changes in the morphology, fibrosis, necrosis, 
and inflammation of kidney and liver were evaluated 
(Figure VA in the online-only Data Supplement).
Ang II infusion for 8 weeks (Figure VB in the online-
only Data Supplement) led to a less pronounced induc-
tion of fibrosis in female mice, which was, however, also 
ameliorated by the 2 lead compounds (Figure VC in the 
online-only Data Supplement). In line with this finding, 
MPI remained almost unchanged among the groups 
tested (Figure VD in the online-only Data Supplement). 
In contrast, Ang II infusion significantly increased iso-
volumic relaxation time/aortic ejection time in female 
mice infused with the solvent only (controls), which 
could be attenuated in animals treated with bufalin or 
lycorine (Figure VE in the online-only Data Supplement). 
The reduced responsiveness of female animals to Ang 
II infusion compared with age-matched male mice is 
likely caused by the presence of estrogen in females; 
the protective effects of estrogen (hypertension and 
cardiovascular disease) are well established.22,23
Collectively, these data emphasize amelioration of 
cardiac function and fibrosis in the diseased heart in a 
therapeutic setting. This may open up novel opportu-
nities for the future treatment of patients with estab-
lished cardiac fibrosis and diastolic dysfunction.
Lycorine and Bufalin Prevent the 
Development of Cardiac Fibrosis and 
Diastolic Dysfunction in Hypertensive Rats
Hypertension is one of the major causes for the devel-
opment of HF with diastolic dysfunction. These patients 
typically exhibit heterogeneous histories of conglomer-
ate risk factors such as diabetes mellitus, dyslipidemia, 
obesity, atrial fibrillation, aging, or renal dysfunction.24 
The Dahl salt-sensitive rat fed a high-salt diet represents 
the most frequently used model of systemic hyperten-
sion–induced HF with diastolic dysfunction, develop-
ing common comorbidities such as dyslipidemia and 
renal failure.25 Moreover, the close reproduction of 
the human cardiac pathophysiology further strength-
ens clinical relevance and thus was used as a supple-
mentary model to test the efficacy of both antifibrotic 
compounds (Figure 4A). Remarkably, evaluation of the 
hearts revealed that fibrosis development was prevent-
ed by both bufalin and lycorine in rats fed a high-salt 
diet. This was evident by near-normal values of collagen 
volume fraction, collagen cross-linking, and collagen 
deposition in whole-heart sections of treated rats (Fig-
ure 4B through 4D). Both bufalin and lycorine showed 
no significant impact on cardiomyocyte size in the Dahl 
salt-sensitive rat model (Figure  4E). Collectively, these 
results imply beneficial fibroblast-specific actions of 
bufalin and lycorine. As expected, echocardiographic 
evaluation of cardiac function revealed progressive dia-
stolic dysfunction in rats fed a high-salt diet, evidenced 
by the reversed hemodynamic parameters tau and dP/
dtmin (borderline significance) and an increased E/A 
ratio. Both compounds improved diastolic properties, 
as reflected by significant reductions of MPI, isovolumic 
relaxation time/aortic ejection time, and E/A and peak 
E/E’ ratios compared with control rats fed a high-salt 
diet (Figure 4F through 4I, Table 3, and Figure VIA in the 
online-only Data Supplement).
Treatment with both compounds had no impact on 
renal inflammation, tubular injury, loss of brush border, 
protein- and detritus-containing casts, thrombotic mi-
croangiopathy, glomerulosclerosis, or arteriosclerosis 
or arteriolosclerosis induced in kidneys by the high-salt 
diet in hypertensive rats (Figure VIB in the online-only 
Data Supplement). Likewise, livers of the hypertensive 
rats showed loss of glycogen and steatosis indepen-
dently of compound treatment. In addition, vessel wall 
Figure 3 Continued. with the solvent only (controls) but not in mice treated with bufalin or lycorine (2-way ANOVA, Tukey multiple-comparisons test, 
n=19/8/7/16/17/16). All values from B through I are presented as mean±SEM. ESPVR indicates end-systolic pressure-volume relationship; and ns, not signifi-
cant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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necrosis and thrombotic microangiopathy were evident 
only in hypertensive animals that did not receive lyco-
rine (Figure VIC in the online-only Data Supplement). 
Again, both compounds showed no effect on heart 
weight or lung weights (Figure VID and VIE in the on-
line-only Data Supplement). Lung water content also 
was not changed among groups (data not shown). 
Weekly dietary food intake was not affected by lead 
compound injections (Figure VIF in the online-only Data 
Supplement), excluding the possibility that the protec-
tive effects are being influenced by factors related to 
high-salt diet consumption.
Profibrotic MicroRNA 671-5p Is a 
Common Effector of the Identified 
Antifibrotic Naturally Derived Substances
To elucidate a potential influence of the identified natu-
ral substances on endogenous microRNAs (miRNAs), 
key posttranscriptional regulators of gene expression, 
miRNA deep sequencing in primary HCFs was per-
formed. Levels of the highly conserved miR-671-5p 
were consistently and significantly reduced after treat-
ment of primary HCFs with all 5 antifibrotic lead com-
pounds from the initial screen in vitro (Figure 5A and 
5B). This result suggested that miR-671-5p might play 
Table 1. Echocardiographic and Hemodynamic Parameters of the Therapeutic Approach in an Ang II–Infused Mouse Model
Vehicle Group Ang II Group
DMSO Bufalin Lycorine DMSO Bufalin Lycorine
Echocardiographic parameters
  Heart rate, bpm 458±38.56 460±59.64 426.8±29.38 455.8±55.64 440.1±41.56 450.9±42.35
  LVEDV, mL 75.21±9.54 71.83±9.91 71.41±9.19 69.52±26.74 79.98±33.06 75.30±28.13
  LVESV, mL 25.26±10.65 33.29±15.96 31.51±5.01 33.49±21.11 41.74±30.16 40.49±24.33
  EF, % 67.93±12.25 62.60±10.65 57.38±5.90 58.80±15.70 57.10±14.07 55.58±14.35
  EDD, mm 3.94±0.30 4.05±0.21 4.03±0.22 3.87±0.65 4.14±0.75 4.07±0.60
  ESD, mm 2.39±0.59 2.87±0.54 2.87±0.19 2.83±0.66* 3.03±0.96 3.05±0.82
  FS, % 36.20±6.61 31.63±7.28 31.70±3.32 30.80±11.92 29.93±9.60 28.97±9.97
  Peak E, cm/s 655±88.68 612.73±112.41 643±78.42 588.9±126.6 569.3±113 550.6±148.31
  Peak A, cm/s 453.9±95.06 444.11±107.99 415.12±61.60 306.7±91.3* 364.04±100.08† 328.6±99.50
  E/A ratio 1.48±0.24 1.41±0.25 1.56±0.11 2.15±0.85* 1.64±0.53(0.08) 1.57±0.56†
  E’, cm/s 20.35±6.48 20.53±3.97 21.65±2.44 13.10±3.12* 16.05±4.26† 14.14±2.69
  A’, cm/s 16.08±3.31 16.56±4.99 18.59±2.35 17.56±5.61 12.65±3.56† 12.12±3.71†
  IVRT, ms 14.13±2.47 13.07±2.26 12.93±5.11 11.67±3.91* 16.12±4.11† 14.62±4.85(0.06)
  IVCT, ms 9.23±3.27 10.46±2.95 11.01±4.78 13.77±3.57* 9.56±3.35† 11.02±3.07†
  LVET, ms 53.83±5.09 52.34±3.69 55.10±6.36 43.67±4.21* 50.00±7.77† 48.12±6.97(0.06)
  LAd, mm 1.93±0.20 1.71±0.34 1.91±0.09 2.15±0.69 1.85±0.45 1.73±0.47
  LAs, mm 0.64±0.23 0.54±0.16 0.64±0.15 1.22±0.46* 0.74±0.11(0.08) 1.05±0.63
Millar parameters
  Heart rate, bpm 453.8±36.07 437.3±20.94 419.9±24.45 415.1±32.85 425.1±52.64 468.3±24.33
  EDPVR 0.087±0.05 0.090±0.03 0.066±0.03 0.26±0.09* 0.087±0.03† 0.084±0.08†
  ESPVR 2.01±0.60 3.89±2.11 1.84±0.66 3.08±1.5 2.91±1.48 4.35±2.12
  Ees/Ea 1.19±0.36 1.99±1.22 1.03±0.26 1.14±0.49 1.39±0.73 1.28±0.74
  dP/dtmax, mm Hg/s 6175±1498 5674±1608 5369±1601 5488±688.7 5549±1271 6167±1552
  dP/dtmin,mm Hg/s −6910±1618 −6174±1770 −6459±1383 −5527±961.6(0.07) -5547±1890 -5689±1530
  Tau, ms 6.25±0.71 7.18±1.20 7.41±0.87 7.78±1.81* 7.52±1.51 7.64±1.56
  SV, mL 41.46±4.86 36.03±7.31 40.54±6.02 30.8±9.47* 39.55±7.41(0.06) 28.58±7.76
  EF, % 57.12±6.28 57.55±17.67 60.69±6.32 45.55±14.43 43.5±11.41 43.53±19.47
Data are expressed as mean±SD. Two-way ANOVA, Tukey multiple-comparisons test. Ang II indicates angiotensin II; dP/dtmax, point of maximum pressure 
increase; dP/dtmin, point of maximum pressure decrease; Ea, arterial elastance; EDD, end diastolic diameter; EDPVR, end-diastolic pressure-volume relationship; EF, 
ejection fraction; ESD, end systolic diameter; ESPVR, end-systolic pressure-volume relationship; FS, fractional shortening; IVCT, isovolumetric contraction time; IVRT, 
isovolumetric relaxation time; LAd, left atrial diastolic size; LAs, left atrial systolic size; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic 
volume; LVET, left ventricular ejection time; SV, stroke volume; and tau (Weiss), time constant of active relaxation.
*Comparison between vehicle-treated and Ang II–treated mice, P<0.05.
†Effect of compounds in Ang II–treated mice, P<0.05).
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a key role in the fibrotic response. Indeed, miR-671-5p 
regulated both fibrosis and inflammatory pathways in 
HCFs. Specific overexpression of miR-671-5 in HCFs led 
to transcriptional activation of α-smooth muscle actin 
(α-SMA), connective tissue growth factor, and the pro-
inflammatory cytokines IL-6 and IL-8, indicating that 
miR-671-5p is sufficient to induce fibrotic and inflam-
matory responses in vitro (Figure  5C and Figure VIIA 
in the online-only Data Supplement). To delineate the 
mechanistic involvement of miR-671-5p in a cellular 
antifibrotic pathway activated by bufalin, the impact 
of miR-671-5p overexpression on transcriptional activa-
tion of α-SMA of primary HCFs on treatment with bufa-
lin was monitored. Bufalin treatment decreased α-SMA 
expression in primary HCFs transfected with miR-mimic 
control or miR-671-5p compared with dimethyl sulfox-
ide control. Antifibrotic effects of bufalin on α-SMA ex-
pression of primary HCFs are significantly disturbed on 
overexpression of miR-671-5p, reflected by elevated α-
SMA expression (Figure 5D), suggesting a role for miR-
671-5p in the antifibrotic efficacy of bufalin.
Because of an intronic localization of miR-671-5p, 
expression of its host gene chondroitin polymerizing 
factor (CHPF) was additionally determined in primary 
HCFs after treatment with the lead compounds. Expres-
sion levels of CHPF, however, did not change consis-
tently in primary HCFs on treatment with the identified 
molecules (Figure VIIB in the online-only Data Supple-
ment), suggesting that the substances do not directly 
drive transcription of the miR-671-5p host gene CHPF.
Consistently, increased miR-671-5p expression could 
be observed in fibrotic conditions in vivo. Cardiac stress 
was induced in wild-type mice via infusion of Ang II. 
Indeed, cell fractionation experiments using hearts of 
mice after implantation of minipumps filled with Ang 
II or vehicle showed a significant and fibroblast-specific 
activation of miR-671-5p (Figure  5E). This activation 
was found to be counteracted by bufalin, confirming 
a possible functional importance of this miRNA in the 
antifibrotic action of bufalin in vivo (Figure VIIC in the 
online-only Data Supplement).
In summary, highly conserved miR-671-5p (accord-
ing to miRBase, http://www.mirbase.org) was deter-
mined as a common effector of the lead compounds 
and as a key player of the fibrotic response in HCFs 
in vitro. Moreover, our studies underscore a functional 
role of miR-671-5p in fibrosis development in vivo and 
highlight its potential clinical importance.
Antifibrotic Selenoprotein P1 Is a Target 
of miR-671-5p in Cardiac Fibroblasts
Bioinformatic analysis using TargetScanHuman (version 
7.1) predicted an 8mer miR-671-5p binding site in the 
3′ untranslated region of selenoprotein P1 (SEPP1) that 
is conserved also in the murine species (Figure 6A). The 
cardioprotective role of the dietary trace element se-
lenium has been shown in a plethora of cardiac stress 
conditions ranging from myocardial hypertrophy to 
diabetes mellitus– and metabolic syndrome–induced 
cardiac stress, ischemia/reperfusion, homocysteine 
dysregulation, and doxorubicin toxicity and is depen-
dent on its incorporation into selenoproteins.26–28 In 
line with this finding, effective silencing of SEPP1 in 
HCFs via siRNA chemistry led to enhanced collagen 
type I, α1 expression in HCFs (Figure VIIE and VIIF in the 
Table 2. Global Strain Analysis of 6 Cardiac Segments of the Therapeutic Approach in Ang II–Infused Mouse Model
Vehicle Ang II
DMSO Bufalin Lycorine DMSO Bufalin Lycorine
RS, %
  Seg 1 39.98±19.28 44.77±14.55 39.55±13.34 14.78±14.33 28.51±23.85 28.89±14.76
  Seg 2 48.49±11.89 35.28±12.58 31.67±9.10 23.87±7.37 28.66±12.13 34.13±14.57
  Seg 3 29.51±12.42 24.38±16.29 28.80±9.40 19.52±11.29 22.83±5.75 24.50±13.96
  Seg 4 41.42±17.66 50.60±21.74 35.38±7.53 31.41±14.77 33.07±12.53 31.84±16.40
  Seg 5 48.76±19.91 49.27±20.17 44.20±6.682 32.19±10.67 31.43±11.20 38.08±17.70
  Seg 6 34.53±17.60 32.51±23.02 27.32±9.81 20.19±9.14 30.73±13.94 30.37±11.98
LS, %
  Seg 1 −19.45±12.80 −16.33±5.99 −13.75±5.92 −7.17±5.92 −10.75±12.02 −10.75±7.53
  Seg 2 −16.42±11.17 −12.94±11.34 −14.69±2.99 −14.39±5.99 −13.03±6.01 −13.67±8.74
  Seg 3 −24.36±10.74 −30.48±7.21 −21.34±3.86 −15.18±10.69 −27.14±9.16 −15.50±8.04
  Seg 4 −11.05±11,08 −10.12±11.59 −12.79±3.92 −9.96±5.92 −7.96±5.75 −10.63±6.26
  Seg 5 −15.59±4.57 −15.66±1.05 −16.13±6.85 −12.80±3.77 −17.34±6.32 −19.09±5.77
  Seg 6 −19.71±4.58 −20.12±11.67 −15.31±3.47 −15.96±5.25 −17.61±5.11 −12.13±6.61
Data are expressed as mean±SD. Ang II indicates angiotensin II; DMSO, dimethyl sulfoxide; LS, longitudinal strain; RS, radial strain; Seg 1, posterior base; Seg 2, 
posterior mid; Seg 3, posterior apex; Seg 4, anterior base; Seg 5, anterior mid; and Seg 6, anterior apex.
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Figure 4. Lycorine and bufalin diminish fibrosis, diastolic dysfunction, and pulmonary congestion in the Dahls salt-sensitive rat.
A, In vivo study using a model of hypertension-induced diastolic dysfunction. Lycorine, bufalin, or dimethyl sulfoxide (DMSO) was injected intraperitoneally every 
other day for 5 consecutive weeks starting 2 weeks after induction of hypertension by a high-salt diet. B through D, Effective and significant reduction of collagen 
volume fraction (CVF; 1-way ANOVA, Tukey multiple-comparisons test, n=17/16/10/13), collagen cross-linking (CCL; 1-way ANOVA, Tukey multiple comparisons 
test, n=17/16/10/13), and collagen accumulation in the myocardium as shown in representative images of Picrosirius red staining; scale bar=1 mm. E, No significant 
impact on cardiomyocyte area shown in representative images and corresponding quantification of heart sections (1-way ANOVA, Tukey multiple-comparisons test, 
n=17/16/10/13); scale bar=200 μm. F through H, Significantly ameliorated myocardial performance index (MPI) and isovolumic relaxation time/aortic ejection time 
(IVRT/AET) in compound-treated rats compared with rats fed a high-salt diet (1-way ANOVA, Tukey multiple-comparisons test, n=10/9/10/13), as well as significant 
reduction of peak E/A (1-way ANOVA, Tukey multiple-comparisons test, n=10/9/10/13) on treatment with lycorine but not with bufalin. I, Representative pulsed-wave 
(PW) Doppler and tissue Doppler images from each group. All values from B, C, and E through H are presented as mean±SEM. *P<0.05, **P<0.01, ***P<0.001. 
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online-only Data Supplement). Repression of SEPP1 by 
miRNA-671-5p would therefore support the detrimen-
tal activity of this miRNA. To validate the bioinformatic 
prediction via TargetScanHuman, we cloned the 3′ un-
translated region of SEPP1 downstream of the firefly 
luciferase gene and found the normalized luciferase 
activity to be markedly reduced on cotransfection of 
the construct with miR-671-5p mimic compared with 
the miR-mimic control (Figure 6B). To prove that SEPP1 
is a target of miR-671-5p in primary HCFs, SEPP1 lev-
els on overexpression of miR-671-5p were monitored. 
Levels of SEPP1 were prominently and significantly 
decreased in primary HCFs after overexpression of 
miR-671-5p (Figure 6C). These data validate SEPP1 as 
a target of miR-671-5p in primary HCFs. SEPP1 levels 
were found to be increased (whereas miR-671-5p lev-
els were decreased) in primary HCFs after treatment 
with the lead antifibrotic substances, particularly gel-
danamycin and bufalin (Figure 6D). These results sug-
gest a protective role of SEPP1, possibly preventing 
myocardial stiffness in vivo. We consistently found that 
expression levels of SEPP1 decreased in fibrotic cardiac 
tissue of mice infused with Ang II for 8 weeks. Ang 
II–induced decline of SEPP1 mRNA was effectively re-
covered by treatment with the lead compounds over a 
time period of 6 weeks. However, no effect on SEPP1 
Table 3. Echocardiographic and Hemodynamic Parameters of the Therapeutic Study Done in the High-Salt Diet–
Induced Rat Model
Normal Diet High-Salt Diet
DMSO DMSO Bufalin Lycorine
Echocardiographic parameters
  Heart rate, bpm 395.4±26.46 368.7±40.85 363.8±26.1 388.3±34.43
  LVEDV, mL 269.9±33.8 299.6±56.78 300.8±49.52 320.5±45.95
  LVESV, mL 44.88±11.33 80.33±28.97* 89.19±37.43 76.49±13.39
  EF, % 83.15±5.04 72.36±6.14* 70.38±12.20 76.07±3.57
  EDD, mm 7.16±0.39 7.36±0.68 7.50±0.56 7.73±0.51
  ESD, mm 3.30±0.349 4.19±0.61* 4.34±0.83 4.14±0.33
  FS, % 53.85±5.58 43.07±5.41* 42.15±10.28 46.44±3.36
  Peak E, cm/s 846±151.6 870.5±113.4 904.1±241.2 889.3±133.1
  Peak A, cm/s 603.8±96.89 552.3±120.8 640.7±181.5 623.9±108.2
  E/A ratio 1.40±0.19 1.83±0.16* 1.43±0.18† 1.31±0.23†
  E’, cm/s −47.34±16.46 −44.25±29.76 −49.85±26.89 −62±24.85
  A’, cm/s −46.52±24.83 −49.54±10.39 −46.46±12.81 −49.94±24.05
  IVRT, ms 11.56±2.69 20.74±3.60* 17.52±3.26(0.09) 13.93±2.22†
  IVCT, ms 16.3±3.66 21.25±3.57* 18.29±1.91(0.06) 17.32±3.84(0.06)
  LVET, ms 61.95±4.38 62.83±3.22 66.23±3.58(0.08) 68.23±7.30(0.09)
Millar parameters
  Heart rate, bpm 346.1±21.65 349.7±22.12 345.1±20.47 362±37.51
  EDPVR, mm Hg/μL 0.054±0.036 0.068±0.099 0.048±0.021 0.055±0.032
  ESPVR, mm Hg/μL 0.89±0.07 1.51±0.66 0.91±0.47 1.03±0.52
  Ees/Ea 1.77±0.21 2.40±1.03 1.39±0.85 1.73±1.06
  dP/dtmax, mm Hg/s 6890±1203 5912±537.9(0.07) 6130±647.3 7510±951.4†
  dP/dtmin, mm Hg/s −8965±1674 −7900±1210(0.09) −8426±1164 −9613±2616(0.100)
  Tau, ms 8.90±1.03 10.06±0.98(0.06) 9.96±1.29 9.20±0.76(0.07)
  SV, mL 228.5±46.97 176±33.52(0.09) 186.1±35.28 216±50.28
  EF, % 92.92±8.46 73.29±10.58* 74.17±13.43 82.97±14.85
Data are expressed as mean±SD. Two-way ANOVA, Tukey multiple-comparisons test. DMSO indicates dimethyl sulfoxide; dP/
dtmax, point of maximum pressure increase; dP/dtmin, point of maximum pressure decrease; Ea, arterial elastance; EDD, end-
diastolic diameter; EDPVR, end-diastolic pressure-volume relationship; EF, ejection fraction; ESD, end-systolic diameter; ESPVR, 
end-systolic pressure-volume relationship; FS, fractional shortening; IVCT, isovolumetric contraction time; IVRT, isovolumetric 
relaxation time; LAd, left atrial diastolic size; LAs, left atrial systolic size; LVEDV, left ventricular end-diastolic volume; LVESV, left 
ventricular end-systolic volume; LVET, left ventricular ejection time; SV, stroke volume; and tau, time constant of active relaxation. 
*Comparison of DMSO control between normal diet and high-salt-diet rats, P<0.05.
†Effect of compounds in high-salt-diet rats, P<0.05.
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mRNA expression was observed with treatment with 
the compounds bufalin or lycorine alone (Figure 6E). 
In line with this finding, rescued SEPP1 protein expres-
sion reduction by Ang II infusion has been shown in 
the bufalin-treated group compared with the dimethyl 
sulfoxide–treated group (Figure VIIH in the online-only 
Data Supplement). Likewise, this normalization was ev-
ident in vitro; bufalin significantly reversed the decline 
of SEPP1 protein associated with Ang II stimulation 
of HCFs (Figure VIIG in the online-only Data Supple-
ment). These results might explain the superior efficacy 
of bufalin both in vitro and in the therapeutic setting 
at applied doses (Figures 1 and 3). To further establish 
the mechanistic role of SEPP1 as a downstream target 
of miR-671-5p, transcriptional activation of α-SMA in 
primary HCFs was followed up after siRNA-mediated 
silencing of SEPP1 on treatment with bufalin. The bu-
falin-induced decline of α-SMA expression in primary 
HCFs was restored by specific silencing of SEPP1 in pri-
mary HCFs via siRNA chemistry (Figure 6F), thereby rep-
licating the impact of repressing SEPP1 by miR-671-5p 
overexpression (Figure  5D). Collectively, these results 
suggest that SEPP1 might be the antifibrotic target of 
miR-671-5p, which partly explains the mechanistic in-
volvement of this miRNA in the antifibrotic efficacy of 
bufalin (Figure 7).
Figure 5. Antifibrotic substances converge on profibrotic microRNA (miR) 671-5p.
A, Representative heat map of differentially regulated miRNAs (unpaired t test P<0.05) and (B) validation of significantly reduced miR-671-5p expression in primary 
human cardiac fibroblasts (HCFs) on treatment as indicated compared with control (unpaired t test, n=3). C, Activation of fibrosis markers α-smooth muscle actin 
(α-SMA), connective tissue growth factor (CTGF), and proinflammatory cytokines interleukin (IL)-6 and IL-8 in primary HCFs after overexpression of miR-671-5p 
(unpaired t test, n=5, miR-mimic control vs miR671-5p mimic). D, Restoration of diminished α-SMA expression of primary HCFs after treatment with bufalin by 
miR-671-5p (2-way ANOVA, Tukey multiple-comparisons test, dimethyl sulfoxide [DMSO] control vs 1 μmol/L bufalin; unpaired t test, miR-mimic control vs miR-
671-5p mimic; n=5). E, MiR-671-5p expression in murine heart cell fractions after infusion with angiotensin II for 2 weeks (unpaired t test, n=6/10). All values from 
B through E are presented as mean±SEM. RNU48 indicates small-nucleolar RNA48. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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DISCUSSION
Here, we show the effective antifibrotic potential of 
the 2 naturally derived compounds bufalin and lycorine 
both in primary HCFs and in multiple rodent models 
of cardiac remodeling in preventive and therapeutic 
settings. Bufalin in particular preserved global and dia-
stolic function of the heart, correlating with a signifi-
cant reduction of collagen deposition. Moreover, bu-
falin ameliorated cardiac function when treatment was 
started at a time point of already established diastolic 
dysfunction, underscoring its clinical translational im-
portance. Both substances were effectively taken up by 
the heart on systemic delivery in vivo. Continuous mon-
itoring of blood pressure via telemetry uncovered that 
neither bufalin nor lycorine shows any antihypertensive 
action on Ang II infusion, excluding the possibility that 
bufalin or lycorine confers cardioprotection by reducing 
elevated blood pressure. When the clinically relevant 
Dahl salt-sensitive rat model was used, fibrosis and dia-
stolic dysfunction were effectively abolished by bufalin 
and lycorine. This result highlights the reproducibility of 
Figure 6. MicroRNA (miR) 671-5p drives fibrosis via repression of selenoprotein P1 (SEPP1).
A, Predicted base pairing between the seed sequence of human miR-671-5p and target sequence in the 3′ untranslated region (UTR) of SEPP1 (TargetScanHuman, 
version 7.1). B, Luciferase activity levels on transfection of a luciferase construct containing the 3′ UTR of SEPP1 with miR-mimic control or miR-671-5p mimic 
(1-sample t test, n=27 replicates). C, Significant reduction of SEPP1 mRNA levels in primary human cardiac fibroblasts (HCFs) after overexpression of miR-671-5p 
(unpaired t test, n=3). D, SEPP1 levels follow the opposite pattern compared with miR-671-5p in primary HCFs on treatment with the lead antifibrotic substances 
(unpaired t test, n=2-3). E, Decrease of SEPP1 levels in cardiac tissue after 8 weeks of angiotensin II infusion (therapeutic mouse study) is significantly counteracted 
by bufalin and lycorine (2-way ANOVA, Tukey multiple-comparison test, n=18/8/7/17/18/16). F, Restoration of diminished α-SMA expression in primary HCFs after 
treatment with bufalin by siRNA-mediated silencing of SEPP1 (2-way ANOVA, Sidak multiple-comparisons test, dimethyl sulfoxide [DMSO] control vs 1 μmol/L 
bufalin; unpaired t test, siRNA control vs siRNA SEPP1; n=4). All values from C through F are presented as mean±SEM. *P<0.05, **P<0.01, ***P<0.001. 
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the antifibrotic effects seen in hypertensive mice in an 
additional species and model.
The cardioprotective potential of bufalin and lyco-
rine may be attributed to their suppressive effects on 
proliferation and collagen production of cardiac fi-
broblasts, the effector cells of fibrosis in the diseased 
heart. Mechanistically, we identified miR-671-5p as a 
common key player of the lead candidates mediating fi-
brosis in primary HCFs. Hence, modulation of miR-671-
5p in the heart might be harnessed as an alternative 
therapeutic strategy for treatment of cardiac fibrotic 
diseases. However, careful risk analysis would be re-
quired because miR-671-5p is ubiquitously expressed in 
various cell types and organs (Figure VIID in the online-
only Data Supplement), which may give rise to unin-
tended off-target effects. In addition, no changes have 
been shown in fibrosis and inflammatory markers with 
sole inhibition of miR-671-5p (Figure VIIA in the online-
only Data Supplement), whereas significant reductions 
of miR-671-5p have been seen in natural compound–
treated animals (Figure 5C), suggesting that additional 
mechanisms are involved in the observed antifibrotic ef-
fect of the compounds.
We found that profibrotic effects of miR-671-5p 
might be mediated by repression of its target SEPP1. 
This protein transports the dietary trace element sele-
nium from the liver to target tissues and was described 
as part of the antioxidant defense line and an important 
cardioprotector.8,26,28,29 Here, we show that SEPP1 is also 
a target of miR-671-5p in primary HCFs, which express 
this protein in remarkably high amounts. Our findings 
imply an antifibrotic, protective role of SEPP1, possibly 
preventing myocardial stiffness in vivo. We consistently 
found expression levels of SEPP1 to be decreased in fi-
brotic cardiac tissue of our murine model of diastolic 
dysfunction caused by prolonged Ang II infusion (ther-
apeutic approach). Bufalin in particular significantly 
recovered SEPP1 levels, possibly explaining apparent 
higher effectivity of this compound in a therapeutic set-
ting.
Despite some efforts to develop new therapeutic 
approaches for the treatment of patients with HF with 
diastolic dysfunction and its progression to end-stage 
systolic HF, the life expectancy of patients remains unac-
ceptably low.30 Cardiovascular diseases still account for 
the highest number of deaths worldwide.3 Myocardial 
fibrosis is a hallmark of cardiac remodeling and a major 
determinant for both the development and progression 
of HF.2 Thus, a breakthrough discovery for a therapeu-
tic strategy to target primarily maladaptive responses 
in cardiac fibroblasts would be indispensable. We pro-
vide evidence for cardioprotective and antifibrotic ef-
fects and the promising safety-tolerability profile of the 
natural compounds bufalin and lycorine, thereby laying 
the groundwork for prospective preclinical and clinical 
studies for both the prevention and treatment of fi-
brotic cardiac diseases. To date, no promising treatment 
for patients with diastolic dysfunction exists. Indeed, the 
understanding of the association between diastolic dys-
function and clinical syndrome of HF is still poor. There-
fore, future clinical testing of compounds that show 
strong cardiac antifibrotic effects and improve diastolic 
function in selected patients with HF should be explored.
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